CG Oncology reported a net loss of $79.1 million, or $(0.90) per share, for the quarter ended June 30, 2026, compared to a $41.4 million loss in the prior year period. Research and development expenses increased to $54.7 million from $31.3 million, while general and administrative expenses rose to $29.0 million from $17.4 million. The company holds approximately $1.0 billion in cash, cash equivalents, and marketable securities as of June 30, 2026, sufficient to fund operations through 2029. Additionally, CG Oncology filed Amendment No. 2 to its Prospectus under an Open Market Sale Agreement with Jefferies LLC, increasing the amount of common stock available for sale by an additional $500.0 million. The company is a late-stage clinical biopharmaceutical firm developing cretostimogene, an investigational oncolytic immunotherapy for bladder cancer.

CG Oncology, Inc. held its 2026 Annual Meeting of Stockholders on June 4, 2026, where stockholders elected Christina Rossi and Victor Tong, Jr. as Class II directors. The meeting also included the ratification of Ernst & Young LLP as the independent registered public accounting firm and advisory votes on executive compensation and the preference for the annual frequency of advisory votes on executive compensation.